heterogeneous nuclear ribonucleoprotein R pseudogene 2Genealiases: []
Q-omics provides the consensus-scored HNRNPRP2 profile across patient tissues and cancer cell-line models. HNRNPRP2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HNRNPRP2 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, HNRNPRP2 RNA expression shows 7,502 significant gene co-expression associations, with the highest sampling consensus in LUSC. Together, these results highlight KIRC, BRCA, and LUSC as cancer lineages where HNRNPRP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPRP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPRP2 survival associations across molecular data types. HNRNPRP2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPRP2 RNA expression–survival associations across cancer types. High HNRNPRP2 expression shows unfavorable associations in KIRC, ACC, BLCA, KICH, UCEC and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HNRNPRP2 RNA expression.
This table summarizes HNRNPRP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPRP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPRP2 shows lower tumor expression in BRCA and THCA. The BRCA box plot shows higher HNRNPRP2 RNA expression in normal versus tumor tissue (log2 FC = −0.014, t-test p = .017).
This table shows molecular features associated with HNRNPRP2 in patient tissues and cancer cell lines. In patient samples, HNRNPRP2 shows the broadest associations at the RNA and protein expression levels, with LUSC recurring as the lineage with the largest associated feature set.
